NCT04895189Completed
Yale COVID-19 Recovery Study
Yale COVID-19 Recovery Vaccine Study: Measuring Changes in Long Covid Symptoms After Vaccination
Source: ClinicalTrials.gov · Last updated 29 May 2025
Brief summary (registry, in English)
The general purpose of the study is to determine the change in immune responses in people with Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) after vaccination. PASC is a disabling, heterogeneous condition in which people have persistent or emerging symptoms months after an initial SARS-CoV-2 infection, (the virus that causes coronavirus disease 2019, or COVID-19. Specifically, the purpose is to enroll participants suffering from moderate-to-severe PASC prior to vaccination and to measure participants' immune and symptom profiles both before and after vaccination. This study is primarily descriptive.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 16 (actual)
- First submitted
- 6 May 2021
- Start date
- 3 May 2021
- Primary completion date
- 9 Jun 2023
- Lead sponsor
- Yale University
- Diseases
- Long COVID and ME/CFS
- NCT number
- NCT04895189
What you commit to
- Study type: Observational
- Participants enrolled: 16
- From 3 May 2021 to the primary completion date, 9 Jun 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Unable to provide informed consent
- Unable to provide 3 blood and saliva samples at one of the 2 participating Yale New Haven Health blood draw sites on a Monday or Wednesday morning (before 12 pm).
- Does not have access to a hand-held device or computer that would allow for digital participation in the study
- Do not have and do not want to set up an email address
- Individuals who are prisoners
Who the study is looking for
- Fluent in English or Spanish
- Age 18 years and over
- Test positive for SARS-CoV-2 (defined as a patient who reports receiving any screening or diagnostic test used to detect the presence of SARS-CoV-2 including any FDA-approved or authorized molecular or antigen-based assay) at least 2 months prior to the start of this study OR test positive for antibodies to SARS-CoV-2 at any point OR receive a positive T-test at any point OR receive a clinical diagnoses of COVID-19 at any point OR was hospitalized due to COVID-19 at any point
- Self-report moderate to severe symptoms or disability due to PASC
- Self-report planning to receive a vaccine against SARS-CoV-2
- Self-report has not yet received any doses of a vaccine against SARS-CoV-2
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Yale New Haven Hospital Coordinator of this site? Confirm its status | New Haven | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.